Start Date
January 16, 2024
Primary Completion Date
October 13, 2031
Study Completion Date
October 13, 2031
Liso-cel
Specified dose on specified days
Idelalisib
Specified dose on specified days
Rituximab
Specified dose on specified days
Bendamustine
Specified dose on specified days
Fludarabine
Specified dose on specified days
Cyclophosphamide
Specified dose on specified days
Local Institution - 0093, Vienna
Local Institution - 0112, Leuven
Local Institution - 0094, Salzburg
Local Institution - 0113, Yvoir
Local Institution - 0121, New York
Stony Brook University, Stony Brook
Local Institution - 0091, Milan
Virginia Oncology Associates, Norfolk
Local Institution - 0083, Kiel
Local Institution - 0068, Morgantown
Local Institution - 0108, Madrid
Local Institution - 0120, Atlanta
Local Institution - 0034, Toulouse
Local Institution - 0036, Montpellier
Local Institution - 0122, Rennes
Local Institution - 0103, Salamanca
Local Institution - 0107, Santander
Local Institution - 0088, Bologna
Local Institution - 0048, Saint Matthews
University Hospitals Cleveland Medical Center, Cleveland
Oncology Hematology Care, Cincinnati
Local Institution - 0106, Valencia
Local Institution - 0082, Cologne
Local Institution - 0058, Iowa City
University Hospital and UW Health Clinics, Madison
Local Institution - 0101, Minneapolis
Local Institution - 0035, Clermont-Ferrand
Local Institution - 0038, Lyon
Local Institution - 0037, Paris
St. David's South Austin Medical Center, Austin
St. Luke's Mountain States Tumor Institute : Boise, Boise
Banner MD Anderson Cancer Center, Gilbert
Local Institution - 0080, Ulm
Local Institution - 0023, Duarte
University of California Davis (UC Davis) Comprehensive Cancer Center, Sacramento
Local Institution - 0084, Dresden
Local Institution - 0081, Leipzig
Local Institution - 0079, Heidelberg
Local Institution - 0114, Amsterdam
Local Institution - 0117, Groningen
Local Institution - 0073, Oslo
Local Institution - 0104, Barcelona
Local Institution - 0105, L'Hospitalet Del Llobregat
Local Institution - 0071, Huddinge
Local Institution - 0115, London
Local Institution - 0109, London
Local Institution - 0111, Leeds
Local Institution - 0110, Oxford
Collaborators (1)
Celgene Corporation
INDUSTRY
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
INDUSTRY